Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2018 | Pages:
99 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The global kidney cancer drugs market size is expected to be valued at USD 6.3 billion by 2022, as per a new report by Grand View Research, Inc., registering a CAGR of 5.4% during the forecast period. Market growth is largely driven by factors such as availability of novel drugs and presence of a strong pipeline. Growth can also be attributed to rise in incidence of renal cancer due to growing geriatric population and changes in lifestyle such as increased smoking and intake of alcohol. In 2012, kidney cancer was the 13th most prevalent cancer worldwide, accounting for approximately 2.0% of all adult malignancies. Kidney and renal pelvis cancer make up for 3.8% of all new cancer cases in U.S. Renal cell carcinoma account for over 90.0% of kidney carcinomas. Various forms of cancer treatment methods have been implemented among the currently approved drugs, including immune modulation therapy, cytokine therapy, mTOR inhibitor, and Vascular Endothelial Growth Factor (VEGF) inhibitor. Further key findings from the report suggest: • Increasing incidence of the disease and rising geriatric population globally are amongst major factors stimulating market growth • Novel agents have expanded market opportunities through larger number of patients under treatment and better treatment prospects compared to traditional therapies. The notable clinical profile of immuno-oncology drugs is reflected their rapid uptake and expansion of indications • The current treatment landscape in metastatic and advanced RCC will shift from TKI and mTOR inhibitors to specific immuno-oncology agents like immune checkpoint inhibitors (ICI), which have demonstrated positive results on PFS as monotherapy (Opdivo) or combination therapy (Opdivo+Yervoy) • U.S. accounted for more than 35.0% of the market in 2016 due to increasing incidence of renal cell carcinoma and presence of key manufacturers in the country. On the other hand, surge in kidney cancer screening is a key driver in markets such as EU • Emerging markets in Asia Pacific and Middle East and Africa are fueled by increasing expenditure on healthcare, a large untapped patient population base due to rise in elderly population, and improvement in diagnostic technologies • Some of the key players operating in this market are Pfizer, Novartis, Bayer, Bristol-Myers Squibb, Eisai, and Exelixis. Collaborations for development, broader product portfolios, and regional expansion in emerging markets are key strategic undertakings of these companies to increase market share.
Table of Contents
Chapter 1 Research Methodology
1.1. Information procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
3.1. Disease Primer
3.2. Epidemiology
Chapter 4 Global Market Overview
4.1 Market by Therapeutic Class
4.2 Market Size and Forecast 2016 - 2022
4.3 Market Share Distribution, by Company 2016 - 2022
4.4 Sales Performance, by Pharmacologic Class
4.5 Market Dynamics and Brand Strategies
4.6 Patent Expiry Analysis
4.7 Kidney Cancer Drugs Market: Drivers and Restraints
4.7.1 Drivers
4.7.2 Challenges
4.8 M&A, Deal Landscape (2013 - 2017 YTD)
4.8.1 Mergers & Acquisitions
4.8.2 Deals Landscape
4.9 Evolution of Biosimilars
4.10 Emerging Markets
4.11 Reimbursement Scenario
4.12 Kidney Cancer Sector SWOT
Chapter 5 Pipeline Intelligence
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Pipeline Landscape
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profiles of Disruptive Drugs
5.3 Global Pipeline Forecast
Chapter 6 Company Profiles
6.1 Pfizer
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Sales Forecast Through 2022
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.4.2 Catalysts & Events Calendar
6.1.5 Pipeline Analysis & Overview
6.1.6 SWOT
6.2 Novartis
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales Through 2022
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.5 Pipeline Analysis & Overview
6.2.6 SWOT
6.3 Bayer
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales Through 2022
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 Pipeline Analysis & Overview
6.3.6 SWOT
6.4 Genentech
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales Through 2022
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.4.2 Catalysts & Events Calendar
6.4.5 Pipeline Analysis & Overview
6.4.6 SWOT
6.5 Bristol-Myers Squibb
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales Through 2022
6.5.4 Strategic Initiatives
6.5.4.1 Key Company News Flow
6.5.4.2 Catalysts & Events Calendar
6.5.5 Pipeline Analysis & Overview
6.5.6 SWOT
6.6 Exelixis
6.6.1 Company Overview
6.6.2 Current Product Portfolio
6.6.3 Product Forecast Sales Through 2022
6.6.4 Strategic Initiatives
6.6.4.1 Key Company News Flow
6.6.4.2 Catalysts & Events Calendar
6.6.5 Pipeline Analysis & Overview
6.6.6 SWOT
6.7 Eisai
6.7.1 Company Overview
6.7.2 Current Product Portfolio
6.7.3 Product Forecast Sales Through 2022
6.7.4 Strategic Initiatives
6.7.4.1 Key Company News Flow
6.7.5 Pipeline Analysis & Overview
6.7.6 SWOT
6.8 Prometheus Labs
6.8.1 Company Overview
6.8.2 Current Product Portfolio
6.8.3 Product Forecast Sales Through 2022
6.8.4 Strategic Initiatives
6.8.4.1 Key Company News Flow
6.8.5 SWOT
Chapter 7 Market Outlook
7.1 What the Future Holds
7.2 The Winners and Losers
7.2.1 Winners
7.2.2 Losers
7.3 Emerging Companies & Technology Platforms
7.4 The Road Ahead
List of Tables TABLE 1 Incidence Rate per 100,000 in Seven Major Markets TABLE 2 Incidence Rate per 100,000 in Forecast, Spain TABLE 3 Marketed Drugs for Kidney Cancer TABLE 4 Marketed Drugs for Kidney Cancer TABLE 5 Sales Performance by Therapeutic Class, 2016 - 22 TABLE 6 Sales Performance by Market, in USD million, 2016 - 22 TABLE 7 Sales Performance by Market, by Pharmacologic Class, 2016 - 22 TABLE 8 Sales Performance by Pharmacologic Class, 2016 - 22 TABLE 9 U.S. Patents for Current Kidney Cancer Drugs TABLE 10 Avastin (bevacizumab) Biosimilars Across Various Indications TABLE 11 R&D Pipeline Overview TABLE 12 Late Stage Pipeline TABLE 13 Bavencio TABLE 14 Tecentriq TABLE 15 Fotivda TABLE 16 Epacadostat TABLE 17 Rocapuldencel-T TABLE 18 Pipeline Forecast TABLE 19 Pfizer Sales Forecast, 2016 - 2022 TABLE 20 Pfizer Pipeline TABLE 21 Novartis Sales Forecast, 2016 - 2022 TABLE 22 Bayer Sales Forecast, 2016 - 2022 TABLE 23 Bayer Pipeline TABLE 24 Genentech (Roche) Sales Forecast, 2016 - 2022 TABLE 25 Genentech (Roche) Pipeline TABLE 26 Bristol-Myers Squibb Sales Forecast, 2016 - 2022 TABLE 27 Bristol-Myers Squibb Pipeline TABLE 28 Exelixis Sales Forecast, 2016 - 2022 TABLE 29 Exelixis Pipeline TABLE 30 Eisai Sales Forecast, 2016 - 2022 TABLE 31 Prometheus Labs Sales Forecast, 2016 - 2022
List of Figures FIG. 1 Market research process FIG. 2 Information Procurement FIG. 3 Primary research pattern FIG. 4 Market research approaches FIG. 5 Value chain based sizing & forecasting FIG. 6 QFD modelling for market share assessment FIG. 7 Race and Gender Specific Prevalence of RCC in the U.S. FIG. 8 Gender Specific Incidence Rate per 100,000 in the U.K. (1993 - 2014) FIG. 9 Kidney Cancer Drugs Market Share, by Therapeutic Class, 2016 - 22 FIG. 10 Regional Market Size, 2016 - 2022 FIG. 11 Market Shares Distribution, 2016 - 2022 FIG. 12 Sales by Pharmacologic Class, 2016 - 2022 FIG. 13 Kidney Cancer SWOT FIG. 14 Pfizer SWOT Analysis FIG. 15 Novartis SWOT Analysis FIG. 16 Bayer SWOT Analysis FIG. 17 Genentech SWOT Analysis FIG. 18 Bristol-Myers Squibb SWOT Analysis FIG. 19 Exelixis SWOT Analysis FIG. 20 Eisai SWOT Analysis FIG. 21 Prometheus Labs SWOT Analysis
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
